APA (7th ed.) Citation

García‐Carbonero, R., van Cutsem, E., Rivera, F., Jassem, J., Gore, I., Tebbutt, N., . . . Hurwitz, H. (2017). Randomized Phase II Trial of Parsatuzumab (Anti‐EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First‐Line Metastatic Colorectal Cancer. The oncologist (Dayton, Ohio), 22(4), 375-e30. https://doi.org/10.1634/theoncologist.2016-0133

Chicago Style (17th ed.) Citation

García‐Carbonero, Rocío, et al. "Randomized Phase II Trial of Parsatuzumab (Anti‐EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First‐Line Metastatic Colorectal Cancer." The Oncologist (Dayton, Ohio) 22, no. 4 (2017): 375-e30. https://doi.org/10.1634/theoncologist.2016-0133.

MLA (9th ed.) Citation

García‐Carbonero, Rocío, et al. "Randomized Phase II Trial of Parsatuzumab (Anti‐EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First‐Line Metastatic Colorectal Cancer." The Oncologist (Dayton, Ohio), vol. 22, no. 4, 2017, pp. 375-e30, https://doi.org/10.1634/theoncologist.2016-0133.